WADA prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-22. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
== Overdose == Reports of overdose indicate that baclofen may cause symptoms including vomiting, general weakness, sedation, respiratory insufficiency, seizures, dizziness, headaches, itching, hypothermia, bradycardia, cardiac conduction abnormalities, hypertension, hyporeflexia and coma sometimes mimicking brain death. Overdose may require intubation and length of mechanical ventilation required may correlate with serum baclofen levels shortly after ingestion. Symptoms may persist even after the point at which serum baclofen levels are undetectable.
== Later research == Reichelt published a number of papers concluding that autistic children excrete higher levels of peptides in their urine, as well as that such peptides may cause autistic gaze aversion; specifically, by interfering with corticothalamocortical processing of visual stimuli. As a result of this theory, others, particularly Panksepp, have speculated that opioid antagonists such as naloxone and naltrexone may be useful in the treatment of autism. In addition, Christopher Gillberg of the University of Gothenburg has published some studies showing that animals treated with opiates exhibit less clinging, in line with the behavior of autistic children, who, his research has also shown, "do not seem concerned when their parents are not near" and "exhibit less crying than infants without autism", and has also linked an excess of endogenous opioids to stereotypic (i.e. repetitive) behavior. However, more recently, two studies were published which failed to find a difference in levels of peptides in the urine of autistic children as opposed to those without autism. A 2009 review found that no evidence exists that urinary peptide levels are correlated with gut permeability.
=== Individual reactions === The removal of the blue checkmark and Twitter Blue have sparked controversy. Actress Alyssa Milano added to her Twitter profile that she would not be paying for Twitter Blue. The Twitter account for Elmo tweeted that, "Elmo will miss you, little blue check mark". The blue checkmark has also caused crosscurrents between Twitter users, with technology journalist Joanna Stern writing that she "likes editing tweets", and appears to have distanced herself from the blue checkmark. Morning Consult journalist Bobby Blanchard asked Twitter to remove his blue checkmark. Other personalities and entities appeared confused as to why their blue checkmarks appeared despite not subscribing to Twitter Blue, such as journalist Maggie Haberman, actors Ben Schwartz and Elijah Wood, astrophysicist Neil deGrasse Tyson, and the Massachusetts Institute of Technology. The Twitter account for the Auschwitz-Birkenau State Museum clarified that it had not paid for Twitter Blue either. Model Chrissy Teigen compared her blue checkmark to the film It Follows (2014) and was able to get hers removed by changing her username, telling speechwriter Jon Favreau. Favreau later stated that he believed Musk was "capricious" in his actions and did not want to be potentially suspended for unverifying his account. Likewise, stand-up comedian and actor Patton Oswalt changed his username to remove his blue checkmark. dril, part of Twitter's secretive list of users to promote and of "Weird Twitter", removed his blue checkmark by changing his display name to "slave to Woke".
Sources: en.wikipedia.org
Most coatings are designed to be microporous in nature, allowing captive moisture within the wall to evaporate outside, whilst not allowing the passage of water to be drawn inside the building, thus largely providing a secondary feature apart from decoration, and that is to weatherproof a wall, and to stop damp forming inside the building. These coatings are intended for on-site application and do not include "factory-applied coatings for building products such as vinyl siding or aluminium window frames [that] may ultimately be used for architectural end-uses".
=== Islamism === Hitchens was deeply shocked by 14 February 1989 fatwa against his longtime friend Salman Rushdie. He became increasingly critical of what he called "theocratic fascism" or "fascism with an Islamic face": radical Islamists who supported the fatwa against Rushdie and sought the recreation of the medieval caliphate. In 2007, Hitchens told New York magazine "If you ask specifically what is wrong with Islam, it makes the same mistakes as the preceding religions, but it makes another mistake, which is that it’s unalterable. You notice how liberals keep saying, “If only Islam would have a Reformation"—it can't have one. It says it can't. It's extremely dangerous in that way". Hitchens is often credited with coining the term "Islamofascism", but Hitchens himself denied it, attributing its coinage to Malise Ruthven. In February 2006, Hitchens helped organize a pro-Denmark rally outside the Danish Embassy in Washington, DC, in response to the Jyllands-Posten Muhammad cartoons controversy. Hitchens has received criticism for his attacks on Islam and has been referred to as Islamophobic. Hitchens has called Islamophobia "A stupid term—Islamophobia—has been put into circulation to try and suggest that a foul prejudice lurks behind any misgivings about Islam's infallible "message".
Merit Award from the National Institute of Health American Society for Bone and Mineral Research Fuller Albright Award Mead Johnson Award Osborne and Mendel Award, the McCollum Award Robert H. Herman Award from the American Society for Clinical Nutrition ACN Award from the American College of Nutrition NIH’s General Clinical Research Center's Program Award for Excellence in Clinical Research Psoriasis Research Achievement Award from the American Skin Association DSM Innovation in Nutrition Award Van Slyke Award from American Association for Clinical Chemistry Linus Pauling Prize In Human Nutrition Delbert A Fisher Research Scholar Award from the Endocrine Society American College of Nutrition's Communication Media Award Institute of Functional Medicine’s LPI Award 2007
Sources: en.wikipedia.org
== Legality == AH-7921 was made a Prohibited Substance (Schedule 9 of the Standard for the Uniform Scheduling of Medicines and Poisons) in Australia in May 2014. Although this amendment was repealed in June 2014, which simply means the amendment document ceases, but the actual scheduling is permanent as part of the main document (all SUSMP amendments cease after a few weeks). It may, however, still be a banned import. AH-7921 has been illegal to distribute in Israel since December 2013. In the UK, AH-7921 was included as a Class A drug in January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014. In Brazil, AH-7921 has been an illegal drug since May 2015. As of October 2015 AH-7921 is a controlled substance in China. AH-7921 is banned in the Czech Republic. In the United States, AH-7921 was placed into Schedule I of the Controlled Substances Act on May 16, 2016, due to its lack of medical use. Furthermore, any person who wishes to manufacture, distribute, import, export, research, and educate using the substance, must be registered by the Drug Enforcement Administration. The Canadian Controlled Drugs and Substances Act was amended in 2016 to include the substance as a Schedule I substance. Possession without legal authority can result in maximum 7 years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify AH-7921 as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug in Canada.
== History == The first acknowledged case of obesity-related non-alcoholic fatty liver was observed in 1952 by Samuel Zelman. Zelman started investigating after observing a fatty liver in a hospital employee who drank more than twenty bottles of Coca-Cola a day. He then went on to design a trial for a year and a half on 20 people with obesity who did not have alcohol use disorder, finding that about half of them had substantially fatty livers. Fatty liver was, however, linked to diabetes since at least 1784 — an observation picked up again in the 1930s. Studies in experimental animals implicated choline inadequacy in the 1920s and excess sugar consumption in 1949. The name "non-alcoholic steatohepatitis" (NASH) was later defined in 1980 by Jurgen Ludwig and his colleagues from the Mayo Clinic to raise awareness of the existence of this pathology, as similar reports previously were dismissed as "patients' lies". This paper was mostly ignored at the time but eventually came to be seen as a landmark paper, and starting in the mid-1990s, the condition began to be intensively studied, with a series of international meetings being held on the topic since 1998. The broader NAFLD term started to be used around 2002. Diagnostic criteria began to be worked out, and in 2005 the Pathology Committee of the NIH NASH Clinical Research Network proposed the NAS scoring system. In 2023, a global consensus panel composed mostly of hepatology researchers and clinicians recommended a change of name to metabolic dysfunction–associated steatotic liver disease (MASLD).
== A == Acetylcholine A neurotransmitter involved in muscle activation, attention, arousal, and memory. It acts at both nicotinic and muscarinic receptors throughout the central and peripheral nervous systems. Achromatopsia Loss of color vision as a result of damage to extrastriate visual cortex. Action Potential A rapid electrical signal that travels down the axon of a neuron. Activation The time-dependent opening of ion channels in response to a stimulus, typically membrane depolarization. Adaptation The phenomenon of sensory receptor adjustment to different levels of stimulation; critical for allowing sensory systems to operate over a wide dynamic range. Adenylyl cyclase Membrane-bound enzyme that can be activated by G-proteins to catalyze the synthesis of cyclic AMP from ATP. Adrenal cortex The outer region of the adrenal gland, responsible for producing steroid hormones such as cortisol and aldosterone, which regulate metabolism and stress responses. Adrenal medulla The central part of the adrenal gland that, under visceral motor stimulation, secretes epinephrine and norepinephrine into the bloodstream. Adrenaline See epinephrine. Afferent nerve fiber An axon that conducts action potentials from the periphery toward the central nervous system. Agnosia The inability to name objects, typically resulting from brain damage in the occipital or temporal lobes. Agonist A chemical that binds to and activates a receptor, mimicking the action of a natural neurotransmitter.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.